Abstract 397: Correlation Between the Whole Blood Omega-Score and Red Blood Cell Membrane Omega-3 Index in a Patient Population with Cardiovascular Disease Risk Factors Treated With a Unique Omega-3 Formulation
Background: Growing evidence supports the value of maintaining a diet rich in omega-3 polyunsaturated fatty acids (PUFA) to achieve longevity of cardiovascular health, and prevent sudden death. Omega-3 deficiency (OM3D) is highly prevalent in the US and contributes to 84,000 deaths/year. To identify patients at risk with OM3D, two laboratory tests are available, including the Omega-Score (OS - whole blood), as well as the Omega-3 Index (OI - red blood cell membrane), that measure omega-3 blood levels. Omega-Score or OI levels <6.1% suggest OM3D. Here we report on the dietary omega-3 status of Canadians, including those with CVD risk factors, through a comparative analysis of the OS vs. OI both pre- and post-treatment with a unique omega-3 formulation.
Methods: Open label study of 143 study subjects enrolled for baseline omega-3 deficiency assessment, of which 63 subjects were scheduled to receive a 4 g/day regimen of a highly purified (>90%) omega-3 formulation (2720 mg/day of EPA + 440 mg/day of DHA), a ratio of 6:1 EPA:DHA (6:1 OM-3) for two weeks, and 31 subjects received 6:1 OM-3 for six weeks. Diagnostic evaluation of the OS, and OI was carried out at baseline, and every two weeks until the study completion.
Results: The majority (84.5%) of subjects tested at baseline had OS levels <6.1%. The baseline, mean OS and OI levels were 3.4% and 4.4% respectively (N=143). After six weeks of treatment, a significant improvement in the OS (120.6% increase, p<0.0001), and OI (72.7% increase, p<0.0001) was observed (N=31). Comparative analysis of the OS vs. the OI resulted in comparable values, with a greater baseline OI, but with near-identical resultant OS an OI levels after six weeks of treatment (7.5%, vs. 7.6% respectively).
Conclusions: This study shows that both the OS and OI provide highly correlative results in the assessment of nutritional omega-3 deficiency, and response to treatment with 6:1 OM-3.
Author Disclosures: G. Jackowski: Employment; Significant; Pivotal Therapeutics Inc. J. Yantha: Employment; Significant; Pivotal Therapeutics Inc. P. Kupchak: Consultant/Advisory Board; Modest; Consultant. N.A. Shaikh: Consultant/Advisory Board; Modest; Adraak Consulting.
- © 2014 by American Heart Association, Inc.